Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen
- 1 August 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 51 (5), 554-561
- https://doi.org/10.1097/qai.0b013e3181adce44
Abstract
Decreased bone mineral density (BMD) has been described in HIV-infected patients initiating antiretroviral therapy (ART), but the contributions of ART and immunologic and/or virologic factors remain unclear. We compared total BMD changes over 96 weeks in 106 ART-naive HIV-infected subjects who were randomized to receive efavirenz (EFV) + zidovudine/lamivudine (n = 32) or lopinavir/ritonavir (LPV/r) + zidovudine/lamivudine induction (n = 74) for 24-48 weeks followed by LPV/r monotherapy. We also sought to identify factors associated with BMD loss, including markers of systemic inflammation [soluble tumor necrosis factor-alpha receptors (sTNFR I and II)]. After 96 weeks, the mean percent change from baseline in total BMD was -2.5% (LPV/r) and -2.3% (EFV) (P < 0.01 for within-group changes in either arm; P = 0.86 for between-group differences). No alteration in the rate of BMD change was observed upon simplification to LPV/r monotherapy. Although soluble tumor necrosis factor-alpha receptor II concentrations at baseline and 24 weeks were at least marginally associated with subsequent changes in BMD (P = 0.06 and P = 0.028, respectively), these associations were no longer significant after adjustment for CD4 T cell count. Subjects with lower baseline CD4 T cell count, non-black race, and higher baseline glucose demonstrated a higher risk for >5% decrease in BMD. Similar decreases in BMD over 96 weeks occurred in ART-naive subjects receiving either EFV-based regimen or LPV/r-based regimen, which was not altered by simplification to LPV/r monotherapy and was unrelated to markers of tumor necrosis factor-alpha activity.Keywords
This publication has 33 references indexed in Scilit:
- Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-AnalysisJournal of Clinical Endocrinology & Metabolism, 2007
- Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic reviewAIDS, 2006
- Modulation of Osteoclastogenesis Induced by Nucleoside Reverse Transcriptase InhibitorsAIDS Research and Human Retroviruses, 2006
- Androgen levels in older men who have or who are at risk of acquiring HIV infection.Clinical Infectious Diseases, 2005
- HIV-1 Vpr enhances production of receptor of activated NF-?B ligand (RANKL) via potentiation of glucocorticoid receptor activityArchiv für die gesamte Virusforschung, 2004
- AZT Enhances Osteoclastogenesis and Bone LossAIDS Research and Human Retroviruses, 2004
- IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiologyCytokine & Growth Factor Reviews, 2004
- HIV Envelope gp120-mediated Regulation of Osteoclastogenesis via Receptor Activator of Nuclear Factor κB Ligand (RANKL) Secretion and Its Modulation by Certain HIV Protease Inhibitors through Interferon-γ/RANKL Cross-talkPublished by Elsevier BV ,2003
- Risk Factors for Coronary Heart Disease in Patients Treated for Human Immunodeficiency Virus Infection Compared with the General PopulationClinical Infectious Diseases, 2003
- Alcohol and Other Substance Use in STD Clinic PatientsSexually Transmitted Diseases, 1994